CAJ | 학술논문

目的：观察通心络胶囊对冠状动脉慢性完全闭塞病变患者血瘀征象及血管新生的影响。方法将67例冠状动脉慢性完全闭塞病变患者（未进行介入或冠状动脉搭桥治疗）随机分为试验组37例和对照组30例。对照组予以常规西药治疗（即合理地给予常规抗血小板、他汀类、β受体阻滞剂、血管紧张素转化酶抑制剂、钙通道阻滞药及硝酸酯类等药物治疗），疗程3个月；试验组在对照组的基础上，加用通心络胶囊3粒，每日3次，口服，治疗3个月。于治疗前后，观察2组患者的血瘀征象，并检测其血管内皮生长因子和碱性成纤维细胞因子水平以及相关不良反应发生率。结果治疗后，2组血瘀征象均较治疗前改善，试验组血瘀证标准计分较对照组显著降低（ P＜0.05）。治疗后，2组血管内皮生长因子、碱性成纤维细胞因子水平较治疗前均明显提高（ P＜0.05），且试验组的血管内皮生长因子、碱性成纤维细胞因子水平高于对照组（ P＜0.05）。治疗期间，2组患者不良反应发生率比较差异无统计学意义（ P＞0.05）。结论通心络胶囊可改善冠状动脉慢性完全闭塞病变患者血瘀征象，升高血管内皮生长因子、碱性成纤维细胞因子水平。
목적：관찰통심락효낭대관상동맥만성완전폐새병변환자혈어정상급혈관신생적영향。방법장67례관상동맥만성완전폐새병변환자（미진행개입혹관상동맥탑교치료）수궤분위시험조37례화대조조30례。대조조여이상규서약치료（즉합리지급여상규항혈소판、타정류、β수체조체제、혈관긴장소전화매억제제、개통도조체약급초산지류등약물치료），료정3개월；시험조재대조조적기출상，가용통심락효낭3립，매일3차，구복，치료3개월。우치료전후，관찰2조환자적혈어정상，병검측기혈관내피생장인자화감성성섬유세포인자수평이급상관불량반응발생솔。결과치료후，2조혈어정상균교치료전개선，시험조혈어증표준계분교대조조현저강저（ P＜0.05）。치료후，2조혈관내피생장인자、감성성섬유세포인자수평교치료전균명현제고（ P＜0.05），차시험조적혈관내피생장인자、감성성섬유세포인자수평고우대조조（ P＜0.05）。치료기간，2조환자불량반응발생솔비교차이무통계학의의（ P＞0.05）。결론통심락효낭가개선관상동맥만성완전폐새병변환자혈어정상，승고혈관내피생장인자、감성성섬유세포인자수평。
Objective To observe the effects of Tongxinluo capsule on the signs of blood stasis and angiogenesis in the chronic total occlusion of coronary heart disease .Methods Sixty-seven patients of chronic total occlusion of coronary heart disease ( which did not undergo percutaneous coronary intervention or coronary artery bypass grafting ) were randomly divided into treatment group ( 37 cases ) and control group ( 30 cases ) . In the control group , the conventional western medicine was applied ( That is legitimately given conventional antiplatelet , statin, βreceptor blocking agents , angiotensin converting enzyme inhibitors , calcium chan-nel blockers and nitrates treatment ).In the treatment group , on the basis of control group , the Tongxinluo capsules 3 pills were taken orally , 3 times per day for 3 months.Before and after 3 months treatment , the signs of blood stasis were observed and the levels of vascular endothelial growth factor ( VEGF) and basic fibroblast growth factor ( bFGF) were determined in two groups. Results The signs of blood stasis were relieved in either group after treatment .The blood stasis standard score in the treatment group was significantly lower than the control group ( P<0.05 ) .After treatment , the level of VEGF and bFGF in both groups were obviously higher than before ( P<0.05 ); the treatment group has a higher level of VEGF and bFGF ( P<0.05 ) compared with the control group .Conclusion Tongxinluo capsule can relieves the signs of blood stasis and elevate the levels of serum VEGF and bFGF of the chronic total occlusion of coronary heart disease .